Safety testing for biological products and viral vaccines.
Introducing comprehensive solutions for safety testing of biological products and viral vaccines.
All biological products must undergo rigorous safety testing at both the development and manufacturing stages to confirm the characteristics of the product and host cells, as well as to ensure non-contamination. ▪ Exceptional technical expertise ▪ Rapid result delivery ▪ Extensive regulatory knowledge ▪ Enhanced quality assurance
basic information
Our company has developed and validated various assays for the characterization of cell banks derived from various species, including mice, hamsters, humans, and primates, and has experience with the following products: ▪ Biosimilar monoclonal antibodies ▪ Monoclonal antibodies ▪ Recombinant proteins ▪ Vaccines ▪ Gene therapy vectors ▪ Regenerative medicine products
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Related Videos
catalog（8）
Download All Catalogs
News about this product（2）
-
[End] Speaker at the Cell Culture Medium Symposium hosted by Shonan I-Park.
This event has concluded. We will be exhibiting and presenting at the Cell Culture Medium Symposium at Shonan, held at Shonan Ai Park on September 13, 2024 (Friday). At our booth, we will introduce Sartorius's wide range of media, raw materials, and services that meet the needs of cell culture. *You can view the program in the "Related Materials." [Event Overview] Date and Time: September 13, 2024 (Friday) 10:00 AM - 5:45 PM Location: Shonan Ai Park or online *Pre-registration required [Our Seminar] Title: Recombumin | Enabling safe and robust manufacturing across various modalities with recombinant human albumin Speaker: Shiori Akiyama (Sales Development Specialist - Cell Lines, Media, Various Tests) Seminar Time: 3:40 PM - 4:10 PM Overview: This seminar will focus on Recombumin, a recombinant human albumin that improves cell viability after cryopreservation and has an effect on suppressing the aggregation of cells and vectors.
-
[Sending recorded video] Cellca Cell Line Development Technical Update: 9 weeks until RCB
Registration for this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. At Sartorius, we have been providing CHO cell line development services that serve as the foundation for the manufacturing of antibody and protein therapeutics. Two products developed through this service have already been launched, and over 40 molecules are currently in clinical development. This webinar will be divided into two parts to introduce this service. In Part 1, we will present the technical upgrades of this service. In Part 2, we will introduce the media products and related services that have been optimized for this service and are now available for general sale. [Seminar Overview] April 6, 2023 (Thursday) 15:00 (approximately 50 minutes) Webinar recorded broadcast [Japanese, free] *We sincerely apologize, but participation from companies in the same industry and email addresses other than those of your organization is not permitted. Thank you for your understanding.
-
[Sending Recorded Video] Services Offered by Sartorius - Introduction to Cell Line Development, Cell Banking, and Various Tests.
Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. There is a growing need to obtain CHO cell lines with high expression levels in as short a time as possible for the development and manufacturing of protein drugs such as antibody therapeutics. Sartorius' Cellca cell line development service has developed over 140 CHO cell lines to date, which are used for commercial or clinical trial manufacturing. In this webinar, we will introduce the technical background, service formats (contract and licensing), as well as the characterization tests and safety tests for antibody drugs, protein drugs, and various cells (gene and cell therapy, vaccines, etc.). *We sincerely apologize, but participation from email addresses other than those of your company or organization is not permitted. Thank you for your understanding.
Recommended products
Distributors
Sartorius Stedim, established in 2007 through the merger of the German company Sartorius, founded in 1870, and the French company Stedim, is a pioneer in "Single-Use Technology (SUT)." As a company capable of providing comprehensive technical support to the pharmaceutical and biotechnology industries, its cutting-edge technology is highly regarded worldwide in the fields of scientific instruments and biotechnology.